Spots Global Cancer Trial Database for Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias

Official Title: A Phase I Study Of Cloretazine™ (VNP40101M) And Temozolomide In Patients With Hematologic Malignancies

Study ID: NCT00098436

Conditions

Leukemia

Interventions

laromustine

temozolomide

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Temozolomide may also help VNP40101M kill more cancer cells by making cancer cells more sensitive to the drug. Giving temozolomide together with VNP40101M may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of temozolomide and VNP40101M in treating patients with relapsed or refractory leukemias.

Detailed Description: OBJECTIVES: * Determine the maximum tolerated dose of temozolomide and VNP40101M in patients with relapsed or refractory leukemias. * Determine the toxic effects of this regimen in these patients. OUTLINE: This is an open-label, dose-escalation, multicenter study. Patients receive oral temozolomide twice daily on days 1-3 (for 5 doses) followed by VNP401010M IV over 15-60 minutes on day 3 (course 1). Patients achieving a complete or partial response or having ≥ 50% reduction in bone marrow blasts may receive a second course of therapy no earlier than day 43. Courses may be repeated approximately every 6 weeks at the discretion of the sponsor and in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of temozolomide until a dose that depletes leukemic blast AGT in at least 4 of 6 patients is determined. Once this dose is determined, cohorts of 3-6 patients receive escalating doses of VNP401010M until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 10 patients are treated at the MTD. PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study.